ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to … Read more
ALPHAHELIX MOL.DIAGN. SK1 (4MB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALPHAHELIX MOL.DIAGN. SK1 - Net Assets Trend (None–None)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALPHAHELIX MOL.DIAGN. SK1 (None–None)
The table below shows the annual net assets of ALPHAHELIX MOL.DIAGN. SK1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALPHAHELIX MOL.DIAGN. SK1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Market Cap
The table below lists competitors of ALPHAHELIX MOL.DIAGN. SK1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mentor Capital Inc.
OTCQB:MNTR
|
$723.43K |
|
Alligator Bioscience AB
ST:ATORX
|
$723.60K |
|
MICRODATA
BC:MICRODATA
|
$724.01K |
|
KRATOS DEF&SEC
MU:WF5A
|
$724.18K |
|
Ankit Metal & Power Limited
NSE:ANKITMETAL
|
$722.48K |
|
Hubilu Venture Corporation
PINK:HBUV
|
$721.52K |
|
Mining Global Inc
PINK:MNGG
|
$721.51K |
|
Benz Mining Corp
PINK:BENZF
|
$721.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALPHAHELIX MOL.DIAGN. SK1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALPHAHELIX MOL.DIAGN. SK1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALPHAHELIX MOL.DIAGN. SK1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALPHAHELIX MOL.DIAGN. SK1's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | €- | N/A | N/A | $723.25K |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |